论文部分内容阅读
目的:评价sIL-2R能否作为早期诊断中枢神经系统白血病(CNSL)及治疗效果监测的敏感指标.方法:采用双抗体夹心酶联免疫吸附法.结果:在发生CNSL时患者脑脊液中sIL-2R平均为89.03±25.12U/ml,显著高于正常对照8.32±3.97U/ml(P<0.01),鞘注化疗后15/20例平均下降至15.56±4.61U/ml,5/20例下降至37.68±6.23U/ml.结论:脑脊液中sIL-2R水平的变化因白血病细胞浸润中枢神经系统而显著升高,并随治疗有效而下降,但部分病例仍持续较高水平.结合临床分析,前者对化疗敏感,后者对化疗相对不敏感,预后差.
OBJECTIVE: To evaluate whether sIL-2R can be used as a sensitive indicator for the early diagnosis of central nervous system leukemia (CNSL) and its efficacy. Methods: Double-antibody sandwich enzyme-linked immunosorbent assay. Results: sIL-2R in cerebrospinal fluid in patients with CNSL The average was 89.03±25.12 U/ml, which was significantly higher than the normal control 8.32±3.97 U/ml (P<0.01). The 15/20 patients after the sheath injection chemotherapy decreased to an average of 15.56±4.61 U/ml, 5/20 cases decreased to 37.68±6.23 U/ml. Conclusion: The change of sIL-2R level in cerebrospinal fluid was significantly increased by leukemia cells infiltrating the central nervous system and decreased with effective treatment. However, some cases continued to be high. Combined with clinical analysis, the former Sensitive to chemotherapy, the latter is relatively insensitive to chemotherapy and has a poor prognosis.